Status:

COMPLETED

Pharmacogenomic Testing in Primary Care

Lead Sponsor:

University of Michigan

Conditions:

Antidepressants Causing Adverse Effects in Therapeutic Use

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This is a 6-month randomized, wait-listed, controlled pilot trial conducted in 6 department of family medicine (DFM) clinics at the University of Michigan (UM). Physicians practicing at a UM DFM clini...

Detailed Description

This is a 6-month randomized, wait-listed, controlled pilot trial conducted in 6 department of family medicine (DFM) clinics at the University of Michigan (UM). We will enroll physicians practicing at...

Eligibility Criteria

Inclusion

  • Physician participants
  • Inclusion criteria:
  • Be a practicing physician at a University of Michigan Department of Family Medicine clinic
  • Be willing to use PGx test results for their patients enrolled in the study
  • Be willing to allow study staff to contact their patients
  • Self-report that they are willing to prescribe antidepressants
  • Exclusion criteria:
  • Do not meet inclusion criteria
  • Patient Participants
  • Inclusion:
  • Be a patient of a participating physician
  • Have a new prescription for one of the following antidepressant medications: citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Prozac Weekly, Rapiflux, Sarafem, Selfemra), fluvoxamine (Luvox, Luvox CR), paroxetine (Paxil, Paxil CR), sertraline (Zoloft), duloxetine (Cymbalta, Irenka), venlafaxine (Effexor), venlafaxine XR (Effexor XR), nortriptyline (Aventyl, Pamelor), bupropion (Forfivo XL, Wellbutrin, Wellbutrin SR, Wellbutrin XL), mirtazapine (Remeron, Remeron Soltab), or vortioxetine (Trintellix)
  • Be willing to undergo PGx testing via single tube blood draw
  • Exclusion:
  • Do not speak English
  • Have previously undergone PGx testing
  • Are unable to provide their own consent to participate in the study
  • Have been taking the new antidepressant prescription for longer than 4 weeks (prior to screening)

Exclusion

    Key Trial Info

    Start Date :

    December 1 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    May 6 2022

    Estimated Enrollment :

    75 Patients enrolled

    Trial Details

    Trial ID

    NCT03270891

    Start Date

    December 1 2017

    End Date

    May 6 2022

    Last Update

    April 11 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Michigan

    Ann Arbor, Michigan, United States, 48109